20.Issue 08 august 21 - INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Volume : 08, Issue : 08, August – 2021

Title:

20.A REVIEW ON ORPHAN DRUGS- INDIAN PERSPECTIVE

Authors :

S Sri Lakshmi Nikhitha*, Vallepu Aswani, T Sai Kishore, Brahmaiah Bonthagarala, Y. Ratna Sindhu, G. Ramakrishna, M. V. Nagabhushanam

Abstract :

WHO defines rare disease as a disease or condition with a prevalence of ≤1/1000 population. Other definitions are diseases affecting <1/2000 population in European union, whereas USFDA defines it as any disorder affecting <200,000 population at a single time point. Ultra rare disease is a disease affecting <2 patients/100,000population. However, rare diseases are indeed not so rare. As most of definitions are based on the prevalence of disease, the orphan disease burden is high in countries with high population. A disease can be rare in a region but may be very common in another region, for example, IgA nephropathy is common in Asia and Africa, but rare in European Union. Lots of issues complicate the drug development process of rare diseases, for example, less understood pathophysiology, lack of validated preclinical models, less research, and lack of standard comparator drug. Clinical issues such as lack of information about natural history of the disease, poorly defined endpoints, poor trial design and inadequate sample size, recruitment problems, lack of well-defined diagnostic criteria, and other issues such as nonexistent comparator drug and funding problems. Although multicentric trials can short out this issue, it has own drawback such as lack of consistency in diagnostic facility in small centers and regional sociocultural variation. Like other drug development, orphan drug developmental is also a costly process. Industries show negligible interest in the development of treatment for rare diseases as there is less return on investment. Mostly, orphan drug research is dependent on government incentives. USFDA, EMEA, Japan, and many other countries offer benefits such as protocol assistance, fast-tract approval, waiver of fees, and marketing exclusivity. In this context, here, we are going to deliberate the different initiatives to accelerate the development of orphan disease research in India.
Keywords: Orphan Drugs, Orphan Diseases.

Cite This Article:

Please cite this article in press S. Sri Lakshmi Nikhitha et al, A Review On Orphan Drugs- Indian Perspective., Indo Am. J. P. Sci, 2021; 08(8).

Number of Downloads : 10

References:

1. Song P, Gao J, Inagaki Y, Kokudo N, Tang W. Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives. Intractable Rare Dis Res. 2012;1:3–9. [PMC free article] [PubMed] [Google Scholar]
2. Report on Orphan Drugs in the Pipeline – Presented by America’s Biopharmaceutical Research Companies. Medicines in Development (2013 Report) [Last accessed on 2017 Sep 09]. Availablefrom: http://www.phrma.docs.phrma.org/sites/default/files/pdf/Rare_Diseases_2013.pd
3. Navaneetham D. Rare Diseases and Disorders – Estimated Rare Diseases Population in South Asian Countries. [Last accessed on 2017 Sep 09]. Available from: http://www.rarediseasesindia.org .
4. Hilgers RD, König F, Molenberghs G, Senn S. Design and analysis of clinical trials for small rare disease populations. J Rare Dis Res Treat. 2016;1:53–60. [Google Scholar]
5. https://www.cbg-meb.nl/over-cbg/het-college
6. G.SaiHanuja, B.SaiKumari, M.V.Nagabhushanam, D.Nagarjuna Reddy, BrahmaiahBonthagarala, Regulatory Requirements for Registration of Generic Drugs in “BRICS” Countries, International Journal of Pharmaceutical Science and Health Care, ISSN 2249 – 5738, Issue 6, Vol. 6 , November-December 2016, 20-40.
7. L Evangeline, NVN Mounica, V Sharmila Reddy, MV Ngabhushanam, D Nagarjuna Reddy and BrahmaiahBonthagarala ,Regulatory process and ethics for clinical trials in India (CDSCO)- A Review, The Pharma Innovation Journal, ISSN (E): 2277- 7695 , ISSN (P): 2349-8242,2017; 6(4): 165-169.
8. 8.B.Sai Kumari, G.SaiHanuja, M.V.Nagabhushanam, D.Nagarjuna Reddy, BrahmaiahBonthagarala, Current Regulatory Requirements for Registration of Medicines, Compilation and Submission of Dossier in Australian Therapeutic goods Administration, International Journal of Advanced Scientific and Technical Research ,ISSN 2249-9954, Issue 6 volume 6, November-December 2016, 144-157.
9. 9.Shaik Salman Basha, S. M. Shakeel, M. V. Nagabhushanam, D. Nagarjuna Reddy, BrahmaiahBonthagarala, The Assesment of Current Regulatory Guidelines for Biosimilars- A Global Scenario, World Journal of Pharmaceutical Research, ISSN 2277– 7105, volume 6, Issue 1, 351-369.
10. 10..S.M.Shakeel, Shaik Salman Basha, M.V.Nagabhushanam, D.Nagarjuna Reddy, BrahmaiahBonthagarala, Comparision of Regulataory Requirements for Generic Drugs Dossier Submission in United States and Canada, International Journal of Pharmaceutical Science and Health Care, ISSN 2249 – 5738, Issue 6, Vol. 6 , November-December 2016, 1-19.
11. 11. Mohanty R, Barick U, Gowda A, Nair A, Mittal S, Patil A. Scope of patient registries for rare diseases in India. Int J Med Res Health Sci. 2016;5:58–61. [Google Scholar]
12. 12. Saikiran Reddy D, Pramodkumar TM, Reddy Y, Sirisha K. Orphan regulations for orphan drug development in India. Asian J Pharm. 2014;8:130. [Google Scholar]
13. 13. Gammie T, Lu CY, Babar ZU. Access to orphan drugs: A Comprehensive review of legislations, regulations and policies in 35 countries. PLoS One. 2015;10:e0140002. [PMC free article] [PubMed] [Google Scholar]
14. 14. Gopal MS. Need to Understand Rare Diseases: Kalam. The Hindu. 2015. [Last accessed on 2017 Aug 02]. Available from: http://www.thehindu.com/news/national/andhra-pradesh/there-is-a-need-to-understand-rare-diseases/article7015624.ece .
15. 15. Waiver of Clinical Trial in Indian Population for Approval of New Drugs Regarding. CDSCO Notice. File No: 12-01/14-DC pt. 47. 2014. Jul 3, [Last accessed on 2017 Sep 22]. Available from http://www.cdsco.nic.in/writereaddata/oo7.pdf .
16. 16. Minutes of the Meeting. Meeting of Pharma Stakeholders with DCG (I) to Explore the Possibilities of Providing Cheaper Medicines, Therapies for Treatment of Rare Disease. 2016. May 04, [Last accessed on 2017 Sep 22]. Available from: http://www.cdsco.nic.in/writereaddata/Minutes%20Of%20Meeting%20Stakeholders%2004_05_2016.pdf .
17. 17. Pharmaceuticals Export Promotion Council of India. [Last accessed on 2017 Sep 22]. Available from: http://www.pharmexcil.com/content/search/orphan .
18. 18. The Indian Rare Disease Registry, ICMR, New Delhi. [Last accessed on 2017 Sep 22]. Available from: http://www.irdr.icmr.org.in/irdr/index.php/diseases-included .
19. 19. ICMR Launches ‘Indian Rare Disease Registry’ to Address Unmet Needs of Patients with Rare Diseases. CheckOrphan. [Last accessed on 2017 Sep 22]. Available from: http://www.checkorphan.org/news/icmr-launches-indian-rare-disease-registry-to-address-unmet-needs-of-patients-with-rare-diseases .
20. 20. Rajasimha HK, Shirol PB, Ramamoorthy P, Hegde M, Barde S, Chandru V, et al. Organization for rare diseases India (ORDI) – Addressing the challenges and opportunities for the Indian rare diseases’ community. Genet Res (Camb) 2014;96:e009. [PubMed] [Google Scholar]
21. 21. Bhuyan A. Government Submits Rare Disease Policy to Delhi HC, Recommends Rs 100 Crore for Genetic Diseases. The Wire. 2017. [Last accessed on 2017 Sep 22]. Available from: https://www.thewire.in/140229/rare-disease-policy/
22. 22. ‘National Policy for Rare Diseases a Welcome Step, Challenges Ahead’ Sunday Guardian. 2017. [Last accessed on 2017 Sep 22]. Available from: http://www.sundayguardianlive.com/news/9732-national-policy-rare-diseases-welcome-step-challenges-ahead.